1
|
Gudde AN, van Velthoven MJJ, Kouwer PHJ, Roovers JPWR, Guler Z. Injectable polyisocyanide hydrogel as healing supplement for connective tissue regeneration in an abdominal wound model. Biomaterials 2023; 302:122337. [PMID: 37793268 DOI: 10.1016/j.biomaterials.2023.122337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2023] [Revised: 09/07/2023] [Accepted: 09/23/2023] [Indexed: 10/06/2023]
Abstract
In pelvic organ prolapse (POP) patients, the uterus, bladder and/or rectum descends into vagina due to weakened support tissues. High recurrence rates after POP surgery suggest an urgent need for improved surgical outcomes. Our aim is to promote connective tissue healing that results in stimulated tissue support functions by surgically applying a hydrogel functionalized with biological cues. We used known vaginal wound healing promoting factors (basic fibroblast growth factor, β-estradiol, adipose-derived stem cells) in the biomimetic and injectable polyisocyanide (PIC) hydrogel, which in itself induces regenerative vaginal fibroblast behavior. The regenerative capacity of injected PIC hydrogel, and the additional pro-regenerative effects of these bioactive factors was evaluated in abdominal wounds in rabbits. Assessment of connective tissue healing (tensile testing, histology, immunohistochemistry) revealed that injection with all PIC formulations resulted in a statistically significant stiffness and collagen increase over time, in contrast to sham. Histological evaluation indicated new tissue growth with moderate to mild immune activity at the hydrogel - tissue interface. The results suggest that PIC injection in an abdominal wound improves healing towards regaining load-bearing capacity, which encourages us to investigate application of the hydrogel in a more translational vaginal model for POP surgery in sheep.
Collapse
Affiliation(s)
- Aksel N Gudde
- Department of Obstetrics and Gynecology, Amsterdam University Medical Center-location AMC, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands; Amsterdam Reproduction and Development, Amsterdam University Medical Center-location AMC, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands
| | - Melissa J J van Velthoven
- Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein Zuid 28, 6525 GA, Nijmegen, the Netherlands; Institute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ, Nijmegen, the Netherlands
| | - Paul H J Kouwer
- Institute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ, Nijmegen, the Netherlands
| | - Jan-Paul W R Roovers
- Department of Obstetrics and Gynecology, Amsterdam University Medical Center-location AMC, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands; Amsterdam Reproduction and Development, Amsterdam University Medical Center-location AMC, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands
| | - Zeliha Guler
- Department of Obstetrics and Gynecology, Amsterdam University Medical Center-location AMC, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands; Amsterdam Reproduction and Development, Amsterdam University Medical Center-location AMC, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.
| |
Collapse
|
2
|
Liu H, Lin X, Xu D, Li J, Fang J, Li J, Meng L, Zeng X, Li Y, Huang J, Guo Z, Zhang X. Radioiodinated Ethinylestradiol Derivatives for Estrogen Receptor Targeting Breast Cancer Imaging. ACS Med Chem Lett 2022; 13:203-210. [PMID: 35178176 PMCID: PMC8842134 DOI: 10.1021/acsmedchemlett.1c00559] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2021] [Accepted: 01/24/2022] [Indexed: 12/30/2022] Open
Abstract
Two novel PEGylated ethinylestradiol (PEG = poly(ethylene glycol)) estrogen receptor (ER) targeting probes [131I]EITE and [131I]MITE were synthesized and evaluated. Both probes had a nanomolar binding affinity to the ER receptor (36.47 nM for [131I]EITE and 61.83 nM for [131I]MITE). They showed high uptake in ER-positive MCF-7 cells and tumors, which could be significantly blocked by a coinjection of excess estradiol. Their ER specificities were further demonstrated by the low uptake in ER-negative MDA-MB-231 cells and tumors. The maximum tumor-to-muscle (T/M) ratios reach to 6.59 for [131I]EITE at 1 h postinjection (p.i.) and to 3.69 for [131I]MITE at 2 h p.i. in MCF-7 tumors. Among these two probes, [131I]EITE showed a faster tumor accumulation and a higher T/M ratio indicating it could be a better candidate for the potential diagnosis of ER-positive breast cancers.
Collapse
Affiliation(s)
- Huanhuan Liu
- State
Key Laboratory of Molecular Vaccinology and Molecular Diagnostics
& Center for Molecular Imaging and Translational Medicine, School
of Public Health, Xiamen University, Xiamen 361102, China
| | - Xiaoru Lin
- State
Key Laboratory of Molecular Vaccinology and Molecular Diagnostics
& Center for Molecular Imaging and Translational Medicine, School
of Public Health, Xiamen University, Xiamen 361102, China
| | - Duo Xu
- State
Key Laboratory of Molecular Vaccinology and Molecular Diagnostics
& Center for Molecular Imaging and Translational Medicine, School
of Public Health, Xiamen University, Xiamen 361102, China
| | - Jingchao Li
- State
Key Laboratory of Molecular Vaccinology and Molecular Diagnostics
& Center for Molecular Imaging and Translational Medicine, School
of Public Health, Xiamen University, Xiamen 361102, China
| | - Jianyang Fang
- State
Key Laboratory of Molecular Vaccinology and Molecular Diagnostics
& Center for Molecular Imaging and Translational Medicine, School
of Public Health, Xiamen University, Xiamen 361102, China
| | - Jindian Li
- State
Key Laboratory of Molecular Vaccinology and Molecular Diagnostics
& Center for Molecular Imaging and Translational Medicine, School
of Public Health, Xiamen University, Xiamen 361102, China
| | - Lingxin Meng
- State
Key Laboratory of Molecular Vaccinology and Molecular Diagnostics
& Center for Molecular Imaging and Translational Medicine, School
of Public Health, Xiamen University, Xiamen 361102, China
| | - Xinying Zeng
- State
Key Laboratory of Molecular Vaccinology and Molecular Diagnostics
& Center for Molecular Imaging and Translational Medicine, School
of Public Health, Xiamen University, Xiamen 361102, China
| | - Yesen Li
- The
First Affiliated Hospital, Xiamen University, Xiamen 361003, China
| | - Jinxiong Huang
- The
First Affiliated Hospital, Xiamen University, Xiamen 361003, China
| | - Zhide Guo
- State
Key Laboratory of Molecular Vaccinology and Molecular Diagnostics
& Center for Molecular Imaging and Translational Medicine, School
of Public Health, Xiamen University, Xiamen 361102, China,
| | - Xianzhong Zhang
- State
Key Laboratory of Molecular Vaccinology and Molecular Diagnostics
& Center for Molecular Imaging and Translational Medicine, School
of Public Health, Xiamen University, Xiamen 361102, China,
| |
Collapse
|
3
|
Radionuclide-Based Imaging of Breast Cancer: State of the Art. Cancers (Basel) 2021; 13:cancers13215459. [PMID: 34771622 PMCID: PMC8582396 DOI: 10.3390/cancers13215459] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2021] [Revised: 10/14/2021] [Accepted: 10/14/2021] [Indexed: 12/21/2022] Open
Abstract
Simple Summary Breast cancer is one of the most commonly diagnosed malignant tumors, possessing high incidence and mortality rates that threaten women’s health. Thus, early and effective breast cancer diagnosis is crucial for enhancing the survival rate. Radionuclide molecular imaging displays its advantages for detecting breast cancer from a functional perspective. Noninvasive visualization of biological processes with radionuclide-labeled small metabolic compounds helps elucidate the metabolic state of breast cancer, while radionuclide-labeled ligands/antibodies for receptor-targeted radionuclide molecular imaging is sensitive and specific for visualization of the overexpressed molecular markers in breast cancer. This review focuses on the most recent developments of novel radiotracers as promising tools for early breast cancer diagnosis. Abstract Breast cancer is a malignant tumor that can affect women worldwide and endanger their health and wellbeing. Early detection of breast cancer can significantly improve the prognosis and survival rate of patients, but with traditional anatomical imagine methods, it is difficult to detect lesions before morphological changes occur. Radionuclide-based molecular imaging based on positron emission tomography (PET) and single-photon emission computed tomography (SPECT) displays its advantages for detecting breast cancer from a functional perspective. Radionuclide labeling of small metabolic compounds can be used for imaging biological processes, while radionuclide labeling of ligands/antibodies can be used for imaging receptors. Noninvasive visualization of biological processes helps elucidate the metabolic state of breast cancer, while receptor-targeted radionuclide molecular imaging is sensitive and specific for visualization of the overexpressed molecular markers in breast cancer, contributing to early diagnosis and better management of cancer patients. The rapid development of radionuclide probes aids the diagnosis of breast cancer in various aspects. These probes target metabolism, amino acid transporters, cell proliferation, hypoxia, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), gastrin-releasing peptide receptor (GRPR) and so on. This article provides an overview of the development of radionuclide molecular imaging techniques present in preclinical or clinical studies, which are used as tools for early breast cancer diagnosis.
Collapse
|
4
|
Xu D, Lin X, Zeng X, Wen X, Li J, Li Y, Huang J, Chen X, Guo Z, Zhang X. Radioiodinated 4-( p-Iodophenyl) Butanoic Acid-Modified Estradiol Derivative for ER Targeting SPECT Imaging. Anal Chem 2021; 93:13998-14006. [PMID: 34612624 DOI: 10.1021/acs.analchem.1c03616] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Overexpression of estrogen receptors (ERs) is one of the important characteristics of most breast cancers. We aim to develop a new type of ER-specific radioiodine-labeled estrogen derivative ([131I]IPBA-EE), which was modified with an albumin-specific ligand 4-(p-iodophenyl) butyric acid (IPBA) to improve the metabolic stability and enhance the ER-targeting ability of estrogen. [131I]IPBA-EE can effectively bind to albumin in vitro, and its dissociation constant (Kd = 0.31 μM) is similar to IPBA (Kd = 0.30 μM). The uptake of [131I]IPBA-EE in ER-positive MCF-7 cells (41.81 ± 3.41%) was significantly higher than that in ER-negative MDA-MB-231 cells (8.78 ± 2.37%, ***P < 0.0005) and could be significantly blocked (3.92 ± 0.35%, ***P < 0.0005). The uptakes of [131I]IPBA-EE in rat uterus and ovaries were 5.66 ± 0.34% ID/g and 5.71 ± 2.77% ID/g, respectively, at 1 h p.i., and these uptakes could be blocked by estradiol (uterus: 2.81 ± 0.41% ID/g, *P < 0.05; ovarian: 3.02 ± 0.08% ID/g, *P < 0.05). SPECT/CT imaging showed that ER-positive MCF-7 tumor uptake of [131I]IPBA-EE reached to 6.07 ± 0.20% ID/g at 7 h p.i., which was significantly higher than that of ER-negative MDA-MB-231 tumor (0.87 ± 0.08% ID/g, **P < 0.005) and could be blocked obviously with fulvestrant (1.65 ± 1.56% ID/g, *P < 0.05). In conclusion, a novel radioiodinated estradiol derivative, [131I]IPBA-EE with albumin-binding property and good metabolic stability, was developed to image the ER in breast cancer. This promising ER-targeted probe has the potential to warrant further preclinical investigations.
Collapse
Affiliation(s)
- Duo Xu
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 4221-116 Xiang'an South Rd, Xiamen 361102, China.,Guangdong Provincial Key Laboratory of Biomedical Imaging and Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai 519000 Guangdong Province, China
| | - Xiaoru Lin
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 4221-116 Xiang'an South Rd, Xiamen 361102, China
| | - Xinying Zeng
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 4221-116 Xiang'an South Rd, Xiamen 361102, China
| | - Xuejun Wen
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 4221-116 Xiang'an South Rd, Xiamen 361102, China
| | - Jingchao Li
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 4221-116 Xiang'an South Rd, Xiamen 361102, China
| | - Yesen Li
- The First Affiliated Hospital of Xiamen University, Zhenhai Road, Xiamen 361003, China
| | - Jinxiong Huang
- The First Affiliated Hospital of Xiamen University, Zhenhai Road, Xiamen 361003, China
| | - Xiaoyuan Chen
- Yong Loo Lin School of Medicine and Faculty of Engineering, National University of Singapore, 1E Kent Ridge Road, Singapore 119228, Singapore
| | - Zhide Guo
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 4221-116 Xiang'an South Rd, Xiamen 361102, China
| | - Xianzhong Zhang
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 4221-116 Xiang'an South Rd, Xiamen 361102, China
| |
Collapse
|
5
|
Fang H, Cavaliere A, Li Z, Huang Y, Marquez-Nostra B. Preclinical Advances in Theranostics for the Different Molecular Subtypes of Breast Cancer. Front Pharmacol 2021; 12:627693. [PMID: 33986665 PMCID: PMC8111013 DOI: 10.3389/fphar.2021.627693] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2020] [Accepted: 02/22/2021] [Indexed: 12/29/2022] Open
Abstract
Breast cancer is the most common cancer in women worldwide. The heterogeneity of breast cancer and drug resistance to therapies make the diagnosis and treatment difficult. Molecular imaging methods with positron emission tomography (PET) and single-photon emission tomography (SPECT) provide useful tools to diagnose, predict, and monitor the response of therapy, contributing to precision medicine for breast cancer patients. Recently, many efforts have been made to find new targets for breast cancer therapy to overcome resistance to standard of care treatments, giving rise to new therapeutic agents to offer more options for patients with breast cancer. The combination of diagnostic and therapeutic strategies forms the foundation of theranostics. Some of these theranostic agents exhibit high potential to be translated to clinic. In this review, we highlight the most recent advances in theranostics of the different molecular subtypes of breast cancer in preclinical studies.
Collapse
Affiliation(s)
- Hanyi Fang
- PET Center, Department of Radiology and Biomedical Imaging, School of Medicine, Yale University, New Haven, CT, United States.,Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China
| | - Alessandra Cavaliere
- PET Center, Department of Radiology and Biomedical Imaging, School of Medicine, Yale University, New Haven, CT, United States
| | - Ziqi Li
- PET Center, Department of Radiology and Biomedical Imaging, School of Medicine, Yale University, New Haven, CT, United States.,Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Yiyun Huang
- PET Center, Department of Radiology and Biomedical Imaging, School of Medicine, Yale University, New Haven, CT, United States
| | - Bernadette Marquez-Nostra
- PET Center, Department of Radiology and Biomedical Imaging, School of Medicine, Yale University, New Haven, CT, United States
| |
Collapse
|
6
|
Liu P, Wang T, Yang R, Dong W, Wang Q, Guo Z, Ma C, Wang W, Li H, Su X. Preclinical Evaluation of a Novel 99mTc-Labeled CB86 for Rheumatoid Arthritis Imaging. ACS OMEGA 2020; 5:31657-31664. [PMID: 33344817 PMCID: PMC7745438 DOI: 10.1021/acsomega.0c04066] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 08/22/2020] [Accepted: 10/16/2020] [Indexed: 06/12/2023]
Abstract
Early diagnosis and therapy are crucial to control disease progression optimally and achieve a good prognosis in rheumatoid arthritis (RA). Previous study showed that a technetium-99m (99mTc)-labeled TSPO ligand (99mTc-CB256 [2-(8-(2-(bis(pyridin-2-yl)methyl)amino)acetamido)-2-(4-chlorophenyl)H-imidazo[1,2-a]pyridin-3-yl)-N,N-dipropylacetamide] composed of a translocator protein (TSPO) ligand CB86 [[2-(4-chlorophenyl)-8-amino-imidazo[1,2-a]-pyridin-3-yl]-N,N-di-n-propylacetamide] and di-(2-picolyl)amine, a bifunctional chelate agent, was used to image a TSPO-rich cancer cell in vitro; however, few 99mTc-CB256 in vivo evaluation has been reported so far probably due to the cytotoxicity of CB256 (ca. 75 times more than analogous CB86). Herein, we describe a novel TSPO targeting radiopharmaceutical consisting of CB86 and diethylenetriaminepentaacetic acid (DTPA), a conventional bifunctional chelating ligand in clinical trials used to prepare 99mTc-labeled CB86, and its evaluation as a 99mTc-single-photon emission computed tomography (SPECT) probe. The radiosynthesis and characterization of 99mTc-DPTA-CB86 including hydrophilicity and stability tests were determined. Additionally, the binding affinity and specificity of 99mTc-DTPA-CB86 to TSPO were evaluated using RAW264.7 macrophage cells. Biodistribution and 99mTc-SPECT studies were conducted on rheumatoid arthritis (RA) rat models after the injection of 99mTc-DTPA-CB86 with or without co-injection of unlabeled DTPA-CB86. The radiosynthesis of 99mTc-DTPA-CB86 was completed successfully with the labeling yields and radiochemical purity of 95.86 ± 2.45 and 97.45 ± 0.69%, respectively. The probe displayed good stability in vitro and binding specificity to RAW264.7 macrophage cells. In the biodistribution studies, 99mTc-DTPA-CB86 exhibited rapid inflammatory ankle accumulation. At 180 min after administration, 99mTc-DTPA-CB86 uptakes of the left inflammatory ankle were 2.35 ± 0.10 percentage of the injected radioactivity per gram of tissue (% ID/g), significantly higher than those of the normal tissues. 99mTc-SPECT imaging studies revealed that 99mTc-DTPA-CB86 could clearly identify the left inflammatory ankle with good contrast at 30-180 min after injection. Therefore, 99mTc-DTPA-CB86 may be a promising probe for arthritis 99mTc-SPECT imaging.
Collapse
Affiliation(s)
- Peng Liu
- Department of Nuclear
Medicine, Zhongshan Hospital Xiamen University, Xiamen 361004, China
| | - Tingting Wang
- Department of Nuclear
Medicine, Zhongshan Hospital Xiamen University, Xiamen 361004, China
| | - Rongshui Yang
- Department of Nuclear
Medicine, Zhongshan Hospital Xiamen University, Xiamen 361004, China
| | - Wentao Dong
- Department of Nuclear
Medicine, Zhongshan Hospital Xiamen University, Xiamen 361004, China
| | - Qiang Wang
- Department of Nuclear
Medicine, Zhongshan Hospital Xiamen University, Xiamen 361004, China
| | - Zhide Guo
- Center for Molecular Imaging and Translational
Medicine, Xiamen University, Xiamen 361102, China
| | - Chao Ma
- Department of Nuclear
Medicine, Zhongshan Hospital Xiamen University, Xiamen 361004, China
| | - Weixing Wang
- Department of Nuclear
Medicine, Zhongshan Hospital Xiamen University, Xiamen 361004, China
| | - Huaibo Li
- Department of Health Medicine, Zhongshan Hospital Xiamen University, Xiamen 361004, China
| | - Xinhui Su
- Department of Nuclear
Medicine, Zhongshan Hospital Xiamen University, Xiamen 361004, China
| |
Collapse
|
7
|
Xu D, Peng C, Gao F, Guo Z, Zhuang R, Su X, Zhang X. Radioiodinated estradiol dimer for estrogen receptor targeted breast cancer imaging. Chem Biol Drug Des 2020; 96:1332-1340. [PMID: 32603003 DOI: 10.1111/cbdd.13754] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2020] [Revised: 05/29/2020] [Accepted: 06/14/2020] [Indexed: 11/26/2022]
Abstract
The aim of this study was to develop a 1-(2-(2-(2-(1,2,3-triazol)ethoxy)ethoxy)ethyl)-5-[125/131 I]iodo-1,2,3-triazole-diestradiol ([125/131 I]ITE2), for estrogen receptor (ER)-expressing breast cancer imaging with single-photon emission computed tomography (SPECT). [125/131 I]ITE2 was prepared in good radiochemical yield (94.4 ± 0.4%) with high radiochemical purity (>99%). [125/131 I]ITE2 had good stability in vitro and moderate molar activity (0.3 ± 0.2 GBq/µmol). Higher uptake in ER-positive MCF-7 cells than that of ER-negative MDA-MB-231 cells was observed at all time points. Rats biodistribution showed that [131 I]ITE2 had high uptake in ER-abundant uterine and ovarian (5.7 ± 0.4 and 10.1 ± 1.4%ID/g at 1 hr postinjection) and could be blocked by co-injection of estradiol (2.7 ± 0.1 and 5.5 ± 0.4%ID/g) obviously. In the SPECT/CT imaging study, [125 I]ITE2 showed significant higher uptake in MCF-7 tumor (3.1 ± 0.4%ID/g) than that of MDA-MB-231 (0.9 ± 0.1%ID/g). Furthermore, the specific uptake of [125 I]ITE2 in ER-positive MCF-7 tumor could be blocked effectively by preadministration of fulvestrant (1.2 ± 0.4%ID/g). A novel radioiodinated dimeric estrogen was designed and synthesized with promising ER targeting ability and specificity. It is worthy of further investigation to validate the advantages of the dimer in ER-positive breast cancer diagnosis.
Collapse
Affiliation(s)
- Duo Xu
- State Key Laboratory of Molecular Vaccinology and Molecular, Diahgnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, China
| | - Chenyu Peng
- State Key Laboratory of Molecular Vaccinology and Molecular, Diahgnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, China
| | - Fei Gao
- State Key Laboratory of Molecular Vaccinology and Molecular, Diahgnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, China
| | - Zhide Guo
- State Key Laboratory of Molecular Vaccinology and Molecular, Diahgnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, China
| | - Rongqiang Zhuang
- State Key Laboratory of Molecular Vaccinology and Molecular, Diahgnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, China
| | - Xinhui Su
- Zhongshan Hospital Affiliated to Xiamen University, Xiamen, China
| | - Xianzhong Zhang
- State Key Laboratory of Molecular Vaccinology and Molecular, Diahgnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, China
| |
Collapse
|
8
|
Hou Z, Wang Q, Guo Z, Wang T, Wu H, Ma C, Wang W, Su F, Zhang H, Su X. Gadolinium-conjugated CB86: a novel TSPO-targeting MRI contrast agent for imaging of rheumatoid arthritis. J Drug Target 2019; 28:398-407. [PMID: 31530199 DOI: 10.1080/1061186x.2019.1669040] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Zhenyu Hou
- Department of Nuclear Medicine, Zhongshan Hospital Xiamen University, Xiamen, China
| | - Qiang Wang
- Department of Nuclear Medicine, Zhongshan Hospital Xiamen University, Xiamen, China
| | - Zhide Guo
- Center for Molecular Imaging and Translational Medicine, Xiamen University, Xiamen, China
| | - Tingting Wang
- Department of Nuclear Medicine, Zhongshan Hospital Xiamen University, Xiamen, China
| | - Huanhua Wu
- Department of Nuclear Medicine, Zhongshan Hospital Xiamen University, Xiamen, China
| | - Chao Ma
- Department of Nuclear Medicine, Zhongshan Hospital Xiamen University, Xiamen, China
| | - Weixing Wang
- Department of Nuclear Medicine, Zhongshan Hospital Xiamen University, Xiamen, China
| | - Fu Su
- Department of Nuclear Medicine, Zhongshan Hospital Xiamen University, Xiamen, China
| | - Huijuan Zhang
- Department of Radiology, Jinshan Branch, Fujian Provincial Hospital of Fujian Medical University, Fuzhou, China
| | - Xinhui Su
- Department of Nuclear Medicine, Zhongshan Hospital Xiamen University, Xiamen, China
| |
Collapse
|
9
|
Cardoso ME, Tejería E, Rey Ríos AM, Terán M. Development and characterization of a 99m Tc-labeled Neuropeptide Y short analog with potential application in breast cancer imaging. Chem Biol Drug Des 2019; 95:302-310. [PMID: 31709766 DOI: 10.1111/cbdd.13644] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2019] [Revised: 09/03/2019] [Accepted: 09/29/2019] [Indexed: 12/26/2022]
Abstract
The aim of this work was to develop and evaluate a 99m Tc-labeled neuropeptide Y derivative with affinity toward Y1-receptor. The selected amino acid sequence included nine amino acids derived from the C-terminal portion of the NPY complemented with the addition of one cysteine-mercaptoacetic acid moiety to bind the radiometal. Labeling was achieved through the preparation of a 3 + 1 nitrido complex. Physicochemical evaluation, cell uptake, internalization and externalization studies, and competitive assays were performed. Biodistribution experiments were carried out in normal and tumor-bearing mice. A single product with radiochemical purity >90% and high stability was obtained. In vitro analysis showed specific cellular uptake, IC50 of 73.2 nM, and a high internalization rate (80%). Biodistribution studies showed low blood and renal uptake and combined hepatobiliary and urinary elimination. Preliminary studies in mice bearing induced breast tumors rendered promising uptake values.
Collapse
Affiliation(s)
- María Elena Cardoso
- Área de Radioquímica, Facultad de Química, Universidad de la República (UdelaR), Montevideo, Uruguay
| | - Emilia Tejería
- Área de Radioquímica, Facultad de Química, Universidad de la República (UdelaR), Montevideo, Uruguay
| | - Ana María Rey Ríos
- Área de Radioquímica, Facultad de Química, Universidad de la República (UdelaR), Montevideo, Uruguay
| | - Mariella Terán
- Área de Radioquímica, Facultad de Química, Universidad de la República (UdelaR), Montevideo, Uruguay
| |
Collapse
|
10
|
Tejería E, Giglio J, Fernández L, Rey A. Development and evaluation of a 99mTc(V)-nitrido complex derived from estradiol for breast cancer imaging. Appl Radiat Isot 2019; 154:108854. [PMID: 31442798 DOI: 10.1016/j.apradiso.2019.108854] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2019] [Revised: 08/02/2019] [Accepted: 08/11/2019] [Indexed: 01/10/2023]
Abstract
Estrogen receptors are overexpressed in 70% of breast cancer and identification of their presence is important to select the appropriate treatment. This work proposes the preparation and evaluation of an estradiol derived as potential ER imaging agent. Ethinylestradiol was derivatized to introduce a dithiocarbamate function for Tc coordination. Labeling was achieved through the formation of a symmetric Tc(V)-nitrido complex with a radiochemical purity (RCP) > 95%. Physicochemical evaluation, cell uptake, biodistribution in normal animals and in nude mice bearing induced ER + breast tumors showed promising results.
Collapse
Affiliation(s)
- Emilia Tejería
- Área de Radioquímica, Facultad de Química, General Flores 2124, Universidad de La República, 11800, Montevideo, Uruguay
| | - Javier Giglio
- Área de Radioquímica, Facultad de Química, General Flores 2124, Universidad de La República, 11800, Montevideo, Uruguay.
| | - Leticia Fernández
- Área de Radioquímica, Facultad de Química, General Flores 2124, Universidad de La República, 11800, Montevideo, Uruguay
| | - Ana Rey
- Área de Radioquímica, Facultad de Química, General Flores 2124, Universidad de La República, 11800, Montevideo, Uruguay.
| |
Collapse
|
11
|
One-Step 18F-Labeling of Estradiol Derivative for PET Imaging of Breast Cancer. CONTRAST MEDIA & MOLECULAR IMAGING 2018; 2018:5362329. [PMID: 29692688 PMCID: PMC5859795 DOI: 10.1155/2018/5362329] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/19/2017] [Accepted: 01/17/2018] [Indexed: 01/17/2023]
Abstract
Positron emission tomography (PET) imaging is a useful method to evaluate in situ estrogen receptor (ER) status for the early diagnosis of breast cancer and optimization of the appropriate treatment strategy. The 18F-labeled estradiol derivative has been successfully used to clinically assess the ER level of breast cancer. In order to simplify the radiosynthesis process, one-step 18F-19F isotope exchange reaction was employed for the 18F-fluorination of the tracer of [18F]AmBF3-TEG-ES. The radiotracer was obtained with the radiochemical yield (RCY) of ~61% and the radiochemical purity (RCP) of >98% within 40 min. Cell uptake and blocking assays indicated that the tracer could selectively accumulate in the ER-positive human breast cancer cell lines MCF-7 and T47D. In vivo PET imaging on the MCF-7 tumor-bearing mice showed relatively high tumor uptake (1.4~2.3 %D/g) and tumor/muscle uptake ratio (4~6). These results indicated that the tracer is a promising PET imaging agent for ER-positive breast cancers.
Collapse
|
12
|
18F-labeled estradiol derivative for targeting estrogen receptor-expressing breast cancer. Nucl Med Biol 2018; 59:48-55. [PMID: 29466767 DOI: 10.1016/j.nucmedbio.2018.01.003] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2017] [Revised: 12/25/2017] [Accepted: 01/22/2018] [Indexed: 01/01/2023]
Abstract
INTRODUCTION A novel radiotracer 1‑(2‑(2‑(2‑[18F]fluoroethoxy)ethoxy)ethyl)‑1H‑1,2,3‑triazole‑estradiol ([18F]FETE) was successfully synthesized, characterized and evaluated in mice for estrogen receptor (ER)-positive breast cancer targeting with positron emission tomography (PET) imaging. METHODS The tosylate precursor 3 was radiolabeled with 18F and then reacted with 17α‑ethinyl‑estradiol to produce the final [18F]FETE. The physicochemical properties of [18F]FETE were tested in vitro, including determination of the octanol/water partition coefficient, stability and cellular uptake in MCF-7 (ER-positive) and MDA-MB-231 (ER-negative) cells. An ex vivo biodistribution study was performed in normal Sprague Dawley rats, and in vivo microPET imaging was performed on MCF-7 and MDA-MB-231 tumor-bearing mice. The results of biodistribution and PET imaging of [18F]FETE were compared with that of known 16α‑[18F]fuoro‑17β‑estradiol ([18F]FES). Radiation dose estimates for [18F]FETE were also analyzed. RESULTS [18F]FETE was obtained in high radiochemical yield (46.59 ± 8.06%) with high radiochemical purity (>99%) after HPLC purification and high molar activity (15.45 ± 3.15 GBq/μmol). [18F]FETE is a moderate lipophilic compound with good in vitro stability and the total synthesis time was 55 to 65 min. In biodistribution studies, [18F]FETE showed high uptake in the ER-abundant uterine tissue of normal immature SD rats (8.55 ± 1.21 and 6.83 ± 1.70%ID/g at 1 h after intravenous and intraperitoneal injection, respectively), and could be blocked with estradiol effectively (the uterus uptake was decreased to 0.63 ± 0.35%ID/g at 1 h after iv injection). MicroPET imaging of tumor-bearing mice with [18F]FETE at 1 h after iv injection revealed considerable uptake in ER-positive MCF-7 tumors (4.63 ± 0.73%ID/g) that could be inhibited (1.47 ± 0.29%ID/g) and low uptake in ER-negative MDA-MB-231 tumors (1.97 ± 0.36%ID/g). [18F]FES has relatively low uptake in ER-positive tumor (0.24 ± 0.19%ID/g) when compared with [18F]FETE. The adult female effective radiation dose of [18F]FETE in mice was estimated as 0.0022 mSv/MBq. CONCLUSIONS A novel 17α‑ethinyl‑estradiol-based ER probe [18F]FETE was developed with high molar activity and good in vitro stability. Based on the results of bio-evaluation in normal immature rats and tumor-bearing mice, it might be a promising candidate for specific PET imaging of ER-positive breast cancer.
Collapse
|
13
|
Tejería ME, Giglio J, Dematteis S, Rey A. Development and characterization of a 99m Tc-tricarbonyl-labelled estradiol derivative obtained by "Click Chemistry" with potential application in estrogen receptors imaging. J Labelled Comp Radiopharm 2017. [PMID: 28640526 DOI: 10.1002/jlcr.3527] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Assessment of the presence of estrogen receptors in breast cancer is crucial for treatment planning. With the objective to develop a potential agent for estrogen receptors imaging, we present the development and characterization of a 99m Tc-tricarbonyl-labelled estradiol derivative. Using ethinylestradiol as starting material, an estradiol derivative bearing a 1,4-disubstituted 1,2,3-triazole-containing tridentate ligand system was synthesized by "Click Chemistry" and fully characterized. Labelling with high yield and radiochemical purity was achieved through the formation of a 99m Tc-tricarbonyl complex. The radiolabelled compound was stable, exhibited moderate binding to plasma protein (approximately 33%) and lipophilicity in the adequate range (logP 1.3 ± 0.1 at pH 7.4). Studies in MCF7 showed promising uptake values (approximately 2%). However, more than 50% of the activity is quickly released from the cell. Biodistribution experiments in normal rats confirmed the expected "in vivo" stability of the radiotracer but showed very high gastrointestinal and liver activity, which is inconvenient for in vivo applications. Taking into consideration the well-documented influence of the chelating system in the physicochemical and biological behaviour of technetium-labelled small biomolecules, research will be continued using the same pharmacophore but different complexation modalities of technetium.
Collapse
Affiliation(s)
- María Emilia Tejería
- Área Radioquímica, Facultad de Química, Universidad de la Republica, Montevideo, Uruguay
| | - Javier Giglio
- Área Radioquímica, Facultad de Química, Universidad de la Republica, Montevideo, Uruguay
| | - Silvia Dematteis
- Area Inmunología, Facultad de Química, Universidad de la Republica, Montevideo, Uruguay
| | - Ana Rey
- Área Radioquímica, Facultad de Química, Universidad de la Republica, Montevideo, Uruguay
| |
Collapse
|
14
|
Kit-like 18F-labeling of an estradiol derivative as a potential PET imaging agent for estrogen receptor-positive breast cancer. J Radioanal Nucl Chem 2017. [DOI: 10.1007/s10967-017-5245-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
15
|
Akbar MU, Ahmad MR, Shaheen A, Mushtaq S. A review on evaluation of technetium-99m labeled radiopharmaceuticals. J Radioanal Nucl Chem 2016. [DOI: 10.1007/s10967-016-5019-7] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|